Your browser doesn't support javascript.
A dynamic COVID-19 immune signature includes associations with poor prognosis.
Laing, Adam G; Lorenc, Anna; Del Molino Del Barrio, Irene; Das, Abhishek; Fish, Matthew; Monin, Leticia; Muñoz-Ruiz, Miguel; McKenzie, Duncan R; Hayday, Thomas S; Francos-Quijorna, Isaac; Kamdar, Shraddha; Joseph, Magdalene; Davies, Daniel; Davis, Richard; Jennings, Aislinn; Zlatareva, Iva; Vantourout, Pierre; Wu, Yin; Sofra, Vasiliki; Cano, Florencia; Greco, Maria; Theodoridis, Efstathios; Freedman, Joshua D; Gee, Sarah; Chan, Julie Nuo En; Ryan, Sarah; Bugallo-Blanco, Eva; Peterson, Pärt; Kisand, Kai; Haljasmägi, Liis; Chadli, Loubna; Moingeon, Philippe; Martinez, Lauren; Merrick, Blair; Bisnauthsing, Karen; Brooks, Kate; Ibrahim, Mohammad A A; Mason, Jeremy; Lopez Gomez, Federico; Babalola, Kola; Abdul-Jawad, Sultan; Cason, John; Mant, Christine; Seow, Jeffrey; Graham, Carl; Doores, Katie J; Di Rosa, Francesca; Edgeworth, Jonathan; Shankar-Hari, Manu; Hayday, Adrian C.
  • Laing AG; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Lorenc A; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Del Molino Del Barrio I; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Das A; UCL Cancer Institute, University College London, London, UK.
  • Fish M; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Monin L; London School of Hygiene & Tropical Medicine, London, UK.
  • Muñoz-Ruiz M; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • McKenzie DR; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Hayday TS; The Francis Crick Institute, London, UK.
  • Francos-Quijorna I; The Francis Crick Institute, London, UK.
  • Kamdar S; The Francis Crick Institute, London, UK.
  • Joseph M; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Davies D; Regeneration Group, Wolfson Centre for Age-Related Diseases, IoPPN, King's College London, London, UK.
  • Davis R; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Jennings A; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Zlatareva I; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Vantourout P; Department of Plastic and Reconstructive Surgery, Royal Free NHS Foundation Trust, London, UK.
  • Wu Y; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Sofra V; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Cano F; Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Greco M; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Theodoridis E; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Freedman JD; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Gee S; UCL Cancer Institute, University College London, London, UK.
  • Chan JNE; The Francis Crick Institute, London, UK.
  • Ryan S; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Bugallo-Blanco E; The Francis Crick Institute, London, UK.
  • Peterson P; The Francis Crick Institute, London, UK.
  • Kisand K; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Haljasmägi L; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Chadli L; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Moingeon P; Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Martinez L; Department of Inflammation Biology, King's College London, London, UK.
  • Merrick B; Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Bisnauthsing K; Molecular Pathology Research Group, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Brooks K; Molecular Pathology Research Group, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Ibrahim MAA; Molecular Pathology Research Group, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Mason J; Center for Therapeutic Innovation in Immuno-inflammation, Servier, France.
  • Lopez Gomez F; Center for Therapeutic Innovation in Immuno-inflammation, Servier, France.
  • Babalola K; Infectious Diseases Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Abdul-Jawad S; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Cason J; Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Mant C; Infectious Diseases Department, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Seow J; Immunological Medicine, Kings College Hospital NHS Foundation Trust, London, UK.
  • Graham C; The European Bioinformatics Institute (EMBL-EBI) Wellcome Genome Campus, Hinxton, UK.
  • Doores KJ; The European Bioinformatics Institute (EMBL-EBI) Wellcome Genome Campus, Hinxton, UK.
  • Di Rosa F; The European Bioinformatics Institute (EMBL-EBI) Wellcome Genome Campus, Hinxton, UK.
  • Edgeworth J; Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
  • Shankar-Hari M; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Hayday AC; Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
Nat Med ; 26(10): 1623-1635, 2020 10.
Article in English | MEDLINE | ID: covidwho-717130
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF inpatient
Subject
COVID-19
Predicate
PROCESS_OF
Object
inpatient
2. COVID-19 PROCESS_OF Cohort
Subject
COVID-19
Predicate
PROCESS_OF
Object
Cohort
3. COVID-19 PROCESS_OF inpatient
Subject
COVID-19
Predicate
PROCESS_OF
Object
inpatient
4. COVID-19 PROCESS_OF Cohort
Subject
COVID-19
Predicate
PROCESS_OF
Object
Cohort
ABSTRACT
Improved understanding and management of COVID-19, a potentially life-threatening disease, could greatly reduce the threat posed by its etiologic agent, SARS-CoV-2. Toward this end, we have identified a core peripheral blood immune signature across 63 hospital-treated patients with COVID-19 who were otherwise highly heterogeneous. The signature includes discrete changes in B and myelomonocytic cell composition, profoundly altered T cell phenotypes, selective cytokine/chemokine upregulation and SARS-CoV-2-specific antibodies. Some signature traits identify links with other settings of immunoprotection and immunopathology; others, including basophil and plasmacytoid dendritic cell depletion, correlate strongly with disease severity; while a third set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression. Hence, contingent upon independent validation in other COVID-19 cohorts, individual traits within this signature may collectively and individually guide treatment options; offer insights into COVID-19 pathogenesis; and aid early, risk-based patient stratification that is particularly beneficial in phasic diseases such as COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Dendritic Cells / B-Lymphocytes / T-Lymphocytes / Cytokines / Coronavirus Infections / Antibodies, Viral Type of study: Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2020 Document Type: Article Affiliation country: S41591-020-1038-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Dendritic Cells / B-Lymphocytes / T-Lymphocytes / Cytokines / Coronavirus Infections / Antibodies, Viral Type of study: Etiology study / Incidence study / Observational study / Prognostic study / Risk factors Language: English Journal: Nat Med Journal subject: Molecular Biology / Medicine Year: 2020 Document Type: Article Affiliation country: S41591-020-1038-6